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Fifty years ago, Richard Doll and A Bradford Hill reported findings
on a cohort of British doctors which demonstrated the strong link
between cigarette smoking and lung cancer (Doll and Hill, 1954). A
summary of the 50-year follow-up of general mortality in that
cohort led by Sir Richard Doll and Sir Richard Peto was recently
published (Doll et al, 2004) and further analyses specific to cancer
mortality will be published in the BJC early in 2005 (Doll et al,
2005) with a separate editorial by Peter Boyle. What is less
frequently appreciated is that an equally prescient paper by Peter
Armitage and Richard Doll was also published 50 years ago in the
BJC on multistage carcinogenesis (Armitage and Doll, 1954). Of
many papers in the BJC that established new insights into the
nature and treatment of cancer, I consider Armitage and Doll
(1954) to be one of the great classics, and we are therefore
reprinting it in this issue.
Armitage and Doll showed that, for a variety of nonendocrine
carcinomas, the incidence of tumours increased with the sixth
power of age. From this observation they postulated the multistage
theory of carcinogenesis and inferred six to seven independent,
sequential and stable events occurring in the cancer lineage before
malignancy became manifest. Although Nordling (1953) had
recently suggested that such ‘hits’ or events were likely to
be successive mutations, Sir Richard tells me that he and Armitage
were cautious not to invoke mutation specifically because of
the acceptance of the ‘two-stage carcinogenesis’ theory based
on experimental tumour production induction using initiating,
mutagenic carcinogens followed by inflammatory, nonmutagenic
promotors such as phorbol esters. The initiator–promotor model
was developed by Isaac Berenblum and Philip Shubik in an-
other early and seminal paper in the BJC (Berenblum and
Shubik, 1949). The multistage theory of carcinogenesis has been
further developed and refined by Armitage and Doll (1957)
themselves, Nick Day (Day and Brown, 1980), Stenback et al
(1981) and by Suresh Moolgavkar (Moolgavkar, 1978; Luebeck and
Moolgavkar, 2002).
The concept of genetic alterations in cancer cells stemmed from
Theodor Boveri’s (1914) observations on aneuploidy in cancer 90
years ago. Yet at the time of Armitage and Doll’s study, despite the
evidence that most carcinogens were mutagens, cancer was still not
universally accepted as a somatic genetic disease. Sir David
Smithers (1962) considered that ‘Cancer is no more a disease of
cells than a traffic jam is a disease of cars. A lifetime’s study of the
internal combustion engine will not explain it’. But in the 50 years
since the Armitage and Doll published their theory, the clonal
evolution of cancer has been repeatedly demonstrated (Nowell,
1976; Greaves, 2002), and many of the specific genes and signalling
pathways have been elucidated that permit tumour cells to
proliferate (Fearon and Vogelstein, 1991; Vogelstein and Kinzler,
2004) and spread (Hunter, 2004). These mutations include
progressive instability of the cancer cell genome (Loeb, 1991;
Cairns, 2002; Feldser et al, 2003), which may itself accelerate the
number of hits in relation to age. Recent mathematical treatments
of somatic mutation in multistage carcinogenesis have emphasized
a Darwinian evolutionary perspective to the process (Greaves,
2002; Gatenby and Vincent, 2003; Michor et al, 2004). Thus, it
seems truly remarkable that the multistage theory of carcinogen-
esis was established by epidemiologists on the basis of an analysis
of the age-specific incidence of common cancers, prior to the
development of molecular biology. BJC salutes Sir Richard Doll
and Prof Armitage who have continued to contribute actively to
our understanding of cancer for 50 years following their
pioneering early papers.
The development of familial cancers at relatively young ages can
be attributed to the first mutational event being inherited, either as
a dominant trait, or as a recessive tumour suppressor gene as
elucidated for the Rb retinoblastosis locus by Al Knudson (2002).
The affected patients are heterozygous for wild-type and mutant
Rb, which is recessive at the cellular level, but presents as a
dominant inheritance in the multicellular human body owing to
the high probability that one of the target cells will incur a second,
somatic mutation that causes the knockout genotype and hence
allows that cell to progress towards the malignant phenotype. One
can also interpret the vastly greater cancer rates in the large bowel
compared to the small bowel (which has as high a cellular turnover
and renewal) as reflecting lower mutation rates in the sterile
environment of the small intestine, whereas the colon is a
substantial incubator of mutagen-releasing bacteria (Venitt et al,
1986). Thus, mutations in multiple genes that alter coding regions
or affect expression, account for the many steps in carcinogenesis
(Vogelstein and Kinzler, 2004). The functions of the genes
concerned involve inhibition of cell proliferation (tumour
suppressor genes), positive signalling of proliferation and migra-
tion (oncogenes), control of apoptosis, and DNA instability and
repair.
Now that the specific mutations and pathways are becoming
unravelled (Weinstein et al, 1997; Vogelstein and Kinzler, 2004),
novel types of therapeutic agents are being avidly sought and
pursued. Gleevec (imatinib) acts on the oncoprotein created by a
specific chromosome re-arrangement in chronic myelocytic
leukaemia (Ross and Hughes, 2004), something that would surely
delight Boveri were he alive today. Inhibitors of tyrosine kinase
receptors and their downstream signalling pathways present
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Ross and Hughes, 2004). Translational and clinical research of this
kind is specially welcomed by BJC, as well as investigations in
molecular diagnostics, cancer genetics and epidemiology.
One of my own research interests is the development of
malignancy in immunocompromised individuals, such as immu-
nosuppressed transplant patients and those with AIDS. Ever since
Paul Ehrlich first enunciated the immune surveillance hypothesis
of cancer in 1909, it has remained popular among oncologists and
adherents of alternative medicine alike, and it is the basis for
immunotherapy (Blattman and Greenberg, 2004; Maher and
Davies, 2004). However, there is scant evidence for specific T-cell
immunity to naturally occurring nonviral cancer in humans,
although macrophages may play a role in innate immune
surveillance (Alexander, 1976). Analysis of cancer incidence rates
in immunocompromised populations reveals greatly increased
cancer rates only for those tumours that express nonself-antigens
such as those caused by oncogenic viruses: for example, non-
Hodgkin’s B-cell lymphoma, Kaposi’s sarcoma and cervical
carcinoma (Boshoff and Weiss, 2002). I suspect that Armitage
and Doll were correct all along and that, even in immunosup-
pressed conditions, potential cancer cells need to clock up six to
seven sequential mutations before presenting as cancer. If that is
the case, an increase in cancer among immunocompromised
patients may be worthy of further investigation, particularly in the
older age groups.
This is my final editorial as Editor-in-Chief of the BJC. It has
been a privilege and a pleasure to occupy this position for 6 years
and I am delighted to welcome my successor, Adrian Harris. I am
most grateful to each of the Subject Editors who has served the BJC
during this time, as well as the Reviews Editor who has
commissioned a lively new series of topical mini-reviews several
of which are cited in this editorial. My personal thanks must also
go to BJC’s business manager, Julia Maidment, whose name does
not appear on BJC’s title page but who has helped me to guide the
journal throughout my period as Editor, and who has ensured
the smooth coordination with our publisher, Nature Publishing
Group, and our owner, Cancer Research UK. I wish the BJC
and advances in the control of cancer every success in the years
to come.
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